Business
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease
POTOMAC, MD / ACCESS Newswire / April 7, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing innovative treatments for Alzheimer's disease, today announced the activation of a new ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / April 7, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing innovative treatments for Alzheimer's disease, today announced the activation of a new clinical trial site at Tandem Clinical Research A Prolerity Network Site in Metairie, Louisiana, for the Company's ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation in Alzheimer's dementia.","length":489,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1504,"height":890,"url":"https://media.zenfs.com/en/accesswire.ca/f34b4862ffeb453d0c4c0bc0bcbaf3df"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rCU2XzOLdxapFdjmxk0cCQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2OA--/https://media.zenfs.com/en/accesswire.ca/f34b4862ffeb453d0c4c0bc0bcbaf3df","width":960,"height":568},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/G2xzrlrrEMGKXdalhmvWFg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNDIw/https://media.zenfs.com/en/accesswire.ca/f34b4862ffeb453d0c4c0bc0bcbaf3df","width":1200,"height":710}},"href":"https://app.accessnewswire.com/imagelibrary/6710f032-9914-4d81-8db4-35d50a058606/1155441/png.png","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The site, located at 3901 Houma Blvd., Suite 500, Metairie, LA 70006, is led by Principal Investigator Dr. Angela Traylor, an experienced neurologist and psychiatrist who has served as both Principal Investigator and Sub-Investigator across multiple neurology and mental-health clinical studies. She will be supported by a seasoned Clinical Trial Coordination team with extensive experience in patient engagement and clinical-operations management.","length":448,"tagName":"p"},{"type":"text","content":""We are pleased to welcome Tandem Clinical Research as a new clinical partner in the CALMA trial," said Ram Mukunda, CEO of IGC Pharma. "With enrollment now over 70% complete, expanding to this highly qualified investigational site with strong neurological expertise strengthens the trial's geographic reach, and enhances patient access. We look forward to working closely with Dr. Traylor and her team."","length":428,"tagName":"p"},{"type"...